President, Health2 Resources; Co-founder and Executive Director, GTMRx Institute
OLYMPUS DIGITAL CAMERA
GTMRx Institute executive director Katherine (Katie) Capps’ passion for “getting the medications right” draws 30-plus years of senior-level professional experience in health, health care delivery and value-based purchasing.
As co-founder, executive director and board member of the Institute, she collaborates with fellow board members to develop and execute the Institute’s strategy bringing critical stakeholders together, focused on appropriate use of medications and gene therapies. In less than two years the Institute has grown to over 1200 members from 800 companies bound together by the urgent need to optimize outcomes and reduce costs by getting the medications right.
A gifted communicator, she cultivates and manages relationships with stakeholders across the health care and health policy spectrums.
Capps has a long history of collaboration in multi-stakeholder environments. As Health2 Resources’ founder and president, she and her team have helped their clients meet advocacy, policy, outreach, awareness and business goals since 1998. In that capacity, she was instrumental in the launch of the Patient-Centered Primary Care Collaborative, now the Primary Care Collaborative.
Prior to establishing Health2 Resources, Capps served as president of the Alabama Healthcare Council reporting to a statewide CEO business community board. She managed the 76-member (350,000 lives) National Business Coalition on Health coalition’s advocacy, measurement and purchasing efforts leading to a three-year, statewide value-based purchasing contract with the state’s largest health plan.
Before that, Capps served for 12 years as a hospital administrator at both for-profit and not-for-profit hospitals located in metro and rural markets. She also served as executive director of a seven-county Medicare-certified home care agency holding company.
A noted health policy expert, she is frequently invited to write and speak on topics such as comprehensive medication management, value-based care, market-based health reform and the importance of primary and patient-centered care.
She has served as a board member for the National Business Coalition on Health, Washington Adventist Health Foundation, the Institute for Health and Productivity Management (advisory board) and the Healthcare Industry Access Initiative. She was also an early member of the purchaser committee for the National Committee for Quality Assurance and the National Advisory Board of NBCH.
Associate Director, OneOme; GTMRx Workgroup Member
As Associate Director of Medical Affairs at OneOme, Dr. Ghada Elnashar educates and informs key opinion leaders, providers, and other healthcare professionals on pharmacogenomics. She leads in bringing the benefits of precision medicine so as to help improve healthcare outcomes and reduce healthcare costs. Dr. Elnashar completed her residency training in Managed Care at HealthPartners clinics and health plan. She earned her M.S. in Biotechnology from The Johns Hopkins University and her Pharm.D. from the University of Minnesota. Throughout her proliferative career, she helped patients on both the individual and population level.
Co-founder and Chief Executive Officer, PrecisionLife
Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.
Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies.
He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies.
Sr. Director, Therapeutic Area Lead – Cardiovascular and Metabolic Disease, Labcorp Biomarker Solution Center
Dr. Katherine Landschulz joined Covance in 2010 after 13 years of experience with three major pharmaceutical companies where she supported programs spanning discovery through Phase III. At Covance, she supports both biotech and large pharmaceutical companies with biomarker selection and strategy development, laboratory placement for method development and qualification/validation, feasibility study design and advises on the use of translational and exploratory biomarker data in drug development.
Dr. Landschulz has a wide range of experience in drug discovery and development, genomic and proteomic biomarker assay development, translational biomarkers, clinical pharmacogenomics and biomarker strategies for Diabetes/CV. She is the holder of two U.S. patents and has co-authored dozens of publications on across a wide range of therapeutic areas.
Associate Director, Neurological Biomarkers, Labcorp Biomarker Solution Center
Robert Martone is a research scientist with deep expertise in neurodegeneration, neuro-oncology, biomarkers and drug discovery. He investigated hereditary neuropathies and the molecular biology of the blood brain barrier at Columbia University, and subsequently managed a portfolio of drug discovery programs at Wyeth Neuroscience targeting Alzheimer’s and Parkinson’s disease. He was the Neuroscience Therapeutic Area Lead for the Covance Biomarker Center of Excellence, and later established a protein biomarker laboratory at St. Jude Children’s Research Hospital. More recently, he was Director of Pre-Clinical Research at Cognition Therapeutics, later supported late stage biomarker and diagnostics efforts at Biogen. He is currently Associate Director supporting Neurology Biomarkers at the Labcorp Biomarker Solutions Center.
Dr. Mark Roberts, received his PhD in Pharmaceutical Sciences from the University of Nottingham (UK) and has worked in the clinical diagnostics arena for over 20 years, holding senior positions in both the in vitro diagnostic and reference laboratory industries. Dr. Roberts joined Labcorp Drug Development (formerly Covance) in 2012 to spearhead its Companion Diagnostics initiative, designed to assist pharmaceutical and diagnostic companies in drug/ companion diagnostic co-development.
Bob holds the position of Head of Data at Congenica where he and his team are responsible for data strategy in addition to acquisition and standardization of public domain and proprietary data. He has an extensive background analyzing life science data having worked as Informatics Lead at Syngenta as well as Content & Curation Coordinator for the European Nucleotide Archive at EBI.
Dr. Eric Walk is Chief Medical Officer at PathAI in Boston, MA. He is head of the Medical group, overseeing Medical Affairs, Regulatory Affairs, and Clinical Affairs.
Eric has over 20 years of experience in precision medicine, oncology drug development and IVD companion diagnostics development. Prior to joining PathAI, he was Chief Medical and Scientific Officer at Roche Tissue Diagnostics/Ventana Medical Systems, where he led Medical & Scientific Affairs, overseeing the development and FDA clearance/approval of over 20 510k and PMA IVD assays, companion diagnostics and digital pathology algorithms. Eric began his industry career at Novartis Oncology, where he held positions in Early Clinical Development and Translational Medicine, working to implement biomarker and precision medicine strategies for early and late stage targeted oncology therapeutics. Eric is a Phi Beta Kappa graduate of Johns Hopkins University and holds a MD degree from the University of Virginia School of Medicine. He is board certified in Anatomic and Clinical Pathology and is a Fellow of the College of American Pathologists (CAP). He currently is a member of the CAP Personalized Healthcare Committee.